Jonsson Comprehensive Cancer Center: Lung Neoplasms trials

The registry lists 32 Lung Neoplasms studies with Jonsson Comprehensive Cancer Center as lead sponsor. 2 are open to participants now and 3 have results posted.

Early Phase 1 2Phase 1 14Phase 2 11No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung AdenocarcinomaRecruitingNCT07235280Early Phase 1
• Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible ParticipantsRecruitingNCT05978128Not applicable
• Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung CancerCompletedNCT02879994Phase 2Results posted
• Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung CancerTerminatedNCT01532362Not applicableResults posted
• Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)TerminatedNCT01029925Phase 2Results posted
• Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic CancersActive, not recruitingNCT07118176Phase 1
• Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung CancerTerminatedNCT04705025Not applicable
• Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung CancerActive, not recruitingNCT04285671Phase 1/2
• Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer TissuesActive, not recruitingNCT04147494Early Phase 1
• Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line ChemotherapyActive, not recruitingNCT03830918Phase 1/2
• CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingNCT03546361Phase 1
• Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung CancerWithdrawnNCT02451865Phase 1
• Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung CancerCompletedNCT01784640Phase 1
• Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung CancerCompletedNCT01664754Phase 1
• Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central AirwaysCompletedNCT01051037Not applicable
• Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerCompletedNCT00601094Phase 1
• Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and ChemotherapyCompletedNCT00450567
• Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy ParticipantsTerminatedNCT00444223Not applicable
• T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid TumorsCompletedNCT00433407Not applicable
• AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaStatus unknownNCT00324597Phase 1
• Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerStatus unknownNCT00278187Phase 2
• Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00104767Phase 1
• Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung CancerTerminatedNCT00098917Phase 1
• Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung CancerWithdrawnNCT00098462Phase 1/2
• Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00072072Phase 1
• Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00072059Phase 2
• Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung CancerCompletedNCT00062179Phase 2
• INS316 Compared With Saline for Sputum Collection in Diagnosing Lung CancerStatus unknownNCT00033527Not applicable
• Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung CancerCompletedNCT00024076Phase 2
• SU006668 in Treating Patients With Advanced Solid TumorsStatus unknownNCT00024063Phase 1
• ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung CancerStatus unknownNCT00021008Phase 2
• Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco SmokersCompletedNCT00020878Phase 2